Associations of deoxyfructosazine and a peroxisome-proliferating gamma-activated receptor agonist antidiabetic agent have a synergistic activity in the treatment of type 2 diabetes

An association of deoxyfructosazine (2-((1R,2S,3R)(1,2,3,4-tetrahydroxybutyl)-5-(2'S,3'R)(2',3',4'-trihydr oxybutyl pyrazine)) (I) and a peroxisome-proliferating gamma-activated receptor (PPAR psi ) agonist antidiabetic agent (II) is new. Independent claims are also included...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	EVERS MICHEL
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	An association of deoxyfructosazine (2-((1R,2S,3R)(1,2,3,4-tetrahydroxybutyl)-5-(2'S,3'R)(2',3',4'-trihydr oxybutyl pyrazine)) (I) and a peroxisome-proliferating gamma-activated receptor (PPAR psi ) agonist antidiabetic agent (II) is new. Independent claims are also included for (1) pharmaceutical compositions (I) and (II); and (2) their use in the prevention and/or treatment of type 2 diabetes and its complications. La présente invention concerne l'association de déoxyfructosazine et d'un antidiabétique agoniste du récepteur gamma-activé par le proliférateur de peroxisome (PPARy), les compositions pharmaceutiques contenant cette association et leur utilisation dans la prévention et/ ou le traitement du diabète de type 2 et ses complications.